Aligos Therapeutics, Inc. announced into a securities purchase agreement to issue 31,429,266 shares of common stock at an issue price of $0.8193 for the gross proceeds of $25,749,997.6338, 81,054,686 shares of common stock of pre funded warrants at an issue price of $0.8192 for the gross proceeds of $66,399,998.7712, accompanying warrants to purchase up to 56,241,973 shares of common stock for aggregate gross proceeds of $92,149,996.405 on October 23, 2023. The transaction was led by life sciences dedicated investment firm with participation from other new and existing institutional investors including Armistice Capital, Deep Track Capital, EcoR1 Capital and Roche Venture Fund, among others and Lawrence M. Blatt. Each pre-funded warrant will have a nominal exercise price of $0.0001 per share of common stock, will be immediately exercisable and will be exercisable until exercised in full.

The accompanying warrants will have an exercise price of $0.7568 per share of common stock, will be immediately exercisable and will expire on October 25, 2030. The private placement is expected to close on October 25, 2023, subject to the satisfaction of customary closing conditions.